Lakefront Biotherapeutics (GLPGF) Gross Profit (2021 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Gross Profit for 6 consecutive years, with $3.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Gross Profit fell 94.89% year-over-year to $3.5 million in Q2 2026; TTM through Jun 2026 was -$33.5 billion, a 10195.53% decrease from a year earlier, with the FY2025 full-year figure at -$32.3 billion, down 12509.04% from the prior year.
• Gross Profit was $3.5 million for Q2 2026 at Lakefront Biotherapeutics, up from $2.0 million in the prior quarter.
• Over five years, Gross Profit peaked at $565.7 million in Q4 2023 and troughed at -$33.5 billion in Q4 2025.
• A 5-year average of -$1.8 billion and a median of $62.6 million in 2023 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit jumped 420.43% in 2023 and slumped 87750.48% in 2025, its largest moves.
• Over 5 years, Gross Profit stood at -$176.6 million in 2022, then jumped by 420.43% to $565.7 million in 2023, then plunged by 93.24% to $38.3 million in 2024, then tumbled by 87750.48% to -$33.5 billion in 2025, then soared by 100.01% to $3.5 million in 2026.
• The last three Gross Profit figures came in at $3.5 million (Q2 2026), $2.0 million (Q1 2026), and -$33.5 billion (Q4 2025), per Business Quant data.